These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36728219)

  • 1. Real world use of dolutegravir two drug regimens.
    Bowman C; Ambrose A; Kanitkar T; Flores K; Simoes P; Hart J; Hunter A; Akodu J; Barber TJ
    AIDS; 2023 Apr; 37(5):785-788. PubMed ID: 36728219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
    Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
    BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
    Nasreddine R; Yombi JC; Darcis G; Florence E; Allard SD; De Scheerder MA; Henrard S; Demeester R; Messiaen P; Ausselet N; Loeckx M; Delforge M; De Wit S;
    HIV Med; 2023 Mar; 24(3):267-278. PubMed ID: 35938381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
    Galizzi N; Poli A; Galli L; Muccini C; Mastrangelo A; Dell'Acqua R; Maillard M; Bossolasco S; Cinque P; Lazzarin A; Castagna A; Gianotti N
    Int J Antimicrob Agents; 2020 Mar; 55(3):105893. PubMed ID: 31926287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
    Lagi F; Botta A; Kiros ST; Meli M; Borchi B; Cavallo A; Pozzi M; Bartoloni A; Sterrantino G
    Int J Antimicrob Agents; 2022 Jan; 59(1):106465. PubMed ID: 34699933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
    Acosta RK; D'Antoni ML; Mulato A; Yant SR; Cihlar T; White KL
    Antimicrob Agents Chemother; 2022 May; 66(5):e0203821. PubMed ID: 35389236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
    Dueñas-Gutiérrez C; Buzón L; Pedrero-Tomé R; Iribarren JA; De Los Santos I; De la Fuente S; Pousada G; Moran MA; Moreno E; Ferreira E; Gómez J; Troya J
    Viruses; 2023 Apr; 15(4):. PubMed ID: 37112915
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health care resource utilization and costs for treatment-experienced people with HIV switching or restarting antiretroviral regimens since 2018.
    Colson A; Chastek B; Gruber J; Majethia S; Zachry W; Mezzio D; Rock M; Anderson A; Cohen JP
    J Manag Care Spec Pharm; 2024 Aug; 30(8):817-824. PubMed ID: 39088337
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rildo: Real-World Multicenter Study on the Effectiveness and Safety of Single-Tablet Regimen of Dolutegravir plus Rilpivirine in Treatment-Experienced People Living with HIV.
    Hidalgo-Tenorio C; Vinuesa D; García-Vallecillos C; Muñoz-Medina L; Sequera S; Javier R; López-Ruz MÁ; Sadyrbaeva-Dolgova S; Pasquau J
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of dolutegravir two-drug regimens in virologically suppressed people living with HIV: a systematic literature review and meta-analysis of real-world evidence.
    Punekar YS; Parks D; Joshi M; Kaur S; Evitt L; Chounta V; Radford M; Jha D; Ferrante S; Sharma S; Van Wyk J; de Ruiter A
    HIV Med; 2021 Jul; 22(6):423-433. PubMed ID: 33529489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study.
    Schneider S; Blick G; Burke C; Ward D; Benson P; Felizarta F; Green D; Donovan C; Harper G; Merrill D; Metzner AA; Mycock K; Wallis H; Patarroyo J; Brogan AP; Oglesby A
    Infect Dis Ther; 2024 Apr; 13(4):891-906. PubMed ID: 38570443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
    AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
    Suárez-García I; Alejos B; Ruiz-Algueró M; García Yubero C; Moreno C; Bernal E; Pérez-Is L; Zubero Z; de Zárraga Fernández MA; Samperiz Abad G; Jarrín I;
    J Int AIDS Soc; 2021 Jul; 24(7):e25758. PubMed ID: 34291580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trajectories of CD4
    Taramasso L; Falletta A; Ricci E; Orofino G; Squillace N; Menzaghi B; De Socio GV; Molteni C; Pellicanò GF; Gulminetti R; Madeddu G; Sarchi E; Vichi F; Celesia BM; Bonfanti P; Di Biagio A;
    Viruses; 2022 Oct; 14(11):. PubMed ID: 36366413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    Lagi F; Giacomelli A; Borghi V; Ciccullo A; Taramasso L; Madeddu G; D'Ettorre G; Giacometti A; Ducci F; De Vito A; Pincino R; Di Giambenedetto S; Mussini C; Antinori S; Sterrantino G
    J Med Virol; 2023 Oct; 95(10):e29149. PubMed ID: 37805832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of doravirine with dolutegravir dual regimen compared with other dolutegravir-based dual combinations.
    Rossotti R; D'Amico F; Bana NB; Nava A; Rezzonico LF; Raimondi A; Fanti D; Chianura LG; Moioli MC; Vismara C; Puoti M
    HIV Med; 2024 Jun; 25(6):675-683. PubMed ID: 38263787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
    Santevecchi BA; Miller S; Childs-Kean LM
    Ann Pharmacother; 2020 Dec; 54(12):1252-1259. PubMed ID: 32517480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lamivudine plus dolutegravir as a switch strategy in children: three case reports.
    Labate L; Bartalucci C; Taramasso L; Brucci G; Vena A; Bassetti M; Di Biagio A
    New Microbiol; 2024 May; 47(1):111-115. PubMed ID: 38700892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.